Creatv Bio

Creatv Bio is a private diagnostics company pioneering a liquid biopsy platform focused on detecting large, phagocytic circulating cells called Cancer Associated Macrophage-Like Cells (CAMLs). Its core value proposition is the potential for early cancer detection and recurrence monitoring across more than 30 cancer types, using a standard blood draw. The company operates in both the clinical research and biopharma services markets, offering assays for patient stratification, therapy monitoring, and drug development support. Its technology differentiates by targeting CAMLs, which are present from early-stage disease, unlike traditional CTCs often found only in later stages.

Microfluidic-based cell capture and analysis platform targeting Cancer Associated Macrophage-Like Cells (CAMLs) and Circulating Tumor Cells (CTCs) from blood samples for cancer diagnostics.

Creatv Bio competes in the crowded liquid biopsy market against large players like Guardant Health, Freenome, and Grail (Illumina) focused on cell-free DNA, as well as other CTC-based companies. Its differentiation hinges on the unique biology of CAMLs for early-stage detection, but it faces the challenge of proving clinical utility against established and emerging technologies.